CRIS Current Research Information System

MARCHETTI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.039
NA - Nord America 1.478
EU - Europa 922
SA - Sud America 206
AF - Africa 124
Continente sconosciuto - Info sul continente non disponibili 115
OC - Oceania 1
Totale 5.885
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.405
SG - Singapore 884
CN - Cina 755
VN - Vietnam 625
IT - Italia 334
HK - Hong Kong 274
KR - Corea 163
BR - Brasile 154
NL - Olanda 126
BD - Bangladesh 110
DE - Germania 78
IN - India 74
SE - Svezia 70
FR - Francia 57
CI - Costa d'Avorio 47
GB - Regno Unito 45
CA - Canada 44
JP - Giappone 39
FI - Finlandia 35
IE - Irlanda 35
SC - Seychelles 35
RU - Federazione Russa 30
CH - Svizzera 26
ZA - Sudafrica 25
AT - Austria 23
PH - Filippine 21
AR - Argentina 19
JO - Giordania 16
PL - Polonia 15
TH - Thailandia 15
BG - Bulgaria 14
ID - Indonesia 14
CL - Cile 12
JM - Giamaica 8
MX - Messico 8
CO - Colombia 7
IQ - Iraq 7
TW - Taiwan 7
LT - Lituania 6
PK - Pakistan 6
EC - Ecuador 5
ES - Italia 5
TR - Turchia 5
NI - Nicaragua 4
UZ - Uzbekistan 4
VE - Venezuela 4
AL - Albania 3
DZ - Algeria 3
PT - Portogallo 3
TG - Togo 3
UA - Ucraina 3
AE - Emirati Arabi Uniti 2
BE - Belgio 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
HN - Honduras 2
IL - Israele 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
ML - Mali 2
MY - Malesia 2
OM - Oman 2
PE - Perù 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CD - Congo 1
CY - Cipro 1
EE - Estonia 1
EG - Egitto 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
IR - Iran 1
KW - Kuwait 1
LB - Libano 1
LC - Santa Lucia 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
MM - Myanmar 1
MU - Mauritius 1
MZ - Mozambico 1
NO - Norvegia 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
SN - Senegal 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 5.770
Salva come PNG Salva come JPEG
Città #
Singapore 630
Hefei 281
Hong Kong 252
Ashburn 229
Ho Chi Minh City 168
San Jose 166
Seoul 160
Hanoi 154
Santa Clara 95
Beijing 77
Bologna 70
Los Angeles 65
Boardman 59
Council Bluffs 56
Abidjan 47
New York 40
São Paulo 37
Chandler 36
Dublin 34
Milan 31
Dallas 29
Tokyo 29
Buffalo 27
Bengaluru 26
Da Nang 26
Lauterbourg 25
Guangzhou 23
Helsinki 23
Redondo Beach 23
Haiphong 22
Johannesburg 22
Amsterdam 21
Bern 19
Castel Maggiore 17
Amman 16
Vienna 16
Nuremberg 14
Rome 14
Shanghai 14
Turin 14
Frankfurt am Main 13
Munich 13
Sofia 13
Orem 12
Tongling 12
Warsaw 12
Falkenstein 11
Biên Hòa 10
Chicago 10
London 10
Atlanta 9
Lappeenranta 9
Montreal 9
Can Tho 8
Fairfield 8
Ninh Bình 8
Phoenix 8
Princeton 8
Rimini 8
Southend 8
Stockholm 8
Toronto 8
Bari 7
Boston 7
Hyderabad 7
Hải Dương 7
Nanjing 7
Paris 7
Thái Nguyên 7
Zhengzhou 7
Changsha 6
Chennai 6
Columbus 6
Florence 6
Genoa 6
Houston 6
Jakarta 6
Manila 6
Mexico City 6
Moscow 6
Denver 5
Kingston 5
Modena 5
Phú Thọ 5
Quezon City 5
Quận Bình Thạnh 5
Redmond 5
San Francisco 5
San Polo di Torrile 5
Seattle 5
Shenzhen 5
Thái Bình 5
Wuhan 5
Xi'an 5
Bangkok 4
Berlin 4
Boydton 4
Brooklyn 4
Bắc Ninh 4
Chengdu 4
Totale 3.532
Salva come PNG Salva come JPEG
Nome #
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 234
Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience 210
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 179
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes 177
Dual-energy spectral CT in renal cell carcinoma: dawn of a brand-new era? 177
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 177
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 176
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 172
Bone targeting agents in patients with metastatic prostate cancer: State of the art 169
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 168
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 163
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 158
18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal Tumors 157
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 155
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 154
The value of molecular features in predicting efficacy of immuno-combinations in kidney cancer: just a drop in the ocean? 152
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 132
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 131
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 125
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 124
The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis 120
Immunohistochemical expression of EZH2 in germ cell tumors of the testis: New insights into the genesis and epigenetic reprogramming of these fascinating tumors 105
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 104
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 98
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges 97
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 96
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma 93
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1) 90
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 86
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 85
Immunohistochemical expression of Nectin-4 and potential implications for enfortumab vedotin therapy in germ cell tumors of the testis: a preliminary study 84
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 83
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials 82
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 81
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 77
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 76
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? 76
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 75
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 74
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 73
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer 73
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 72
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 69
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma 66
Pathological and Clinical Implications of Tumor Microenvironment Evaluated With Multiplex Immunohistochemistry in Testicular Embryonal Carcinoma 64
Clinical outcomes and prognostic factors in patients with penile carcinoma: a sub-analysis from Meet-URO 23 (I-RARE) registry study 63
Current androgen receptor antagonists under investigation for resistant prostate cancer 59
Prostate cancer and novel pharmacological treatment options - what's new for 2022? 53
Re: First-line Therapy for Advanced Non-Clear Cell Renal Cell Carcinoma. A Systematic Review and Meta-analysis 49
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 43
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial 41
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence 40
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials 39
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study 39
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma 38
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study 32
Totale 5.885
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.867
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.867
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202282 0 0 1 3 2 1 6 20 5 3 29 12
2022/2023341 4 14 7 15 34 32 20 17 90 9 55 44
2023/2024218 19 36 20 14 18 27 6 16 15 12 21 14
2024/20251.409 61 137 96 89 143 58 78 55 34 122 211 325
2025/20263.695 347 445 349 311 347 130 420 111 580 252 191 212
2026/2027128 128 0 0 0 0 0 0 0 0 0 0 0
Totale 5.885